Genmab — November 2018

[Plimsoller]

God morgen:)

[bibob]

God morgen

[bibob]

Dara i solide er vel kursmæssigt pillet ud af casen. Men man kunne frygte at det stadig ville føre til et stort fald hvis Dara/ Opdivo også fejler. Alt bliver brugt til negativ omtale i øjeblikket . !!

[polle1]

God morgen

[E_L]

I am not aware of a Dara/Opdivo AML trial? Not sure he is correct?

[Plimsoller]

Something for Q&A?

[Bulder]

It's a preclinical study, but I don't see any sign of Opdivo in that tweet. Only ATRA.

[Solsen]

3 clinical trails with dara in AML in search on CT

[Solsen]

https://clinicaltrials.gov/ct2/results?cond=aml&term=daratumumab+&cntry=&state=&city=&dist= no one with Opdivo

[AaBforever]

Det ser ud til at Genmab osse skal en over nakken i dag..:-(

[bibob]

Der er da ingen handel. ? Hvis AB vender kan vi da hurtigt få både handel og stigninger.

[gentogen]

Angående Ofatumumab hed den oprindelige aftale, at "Genmab will be entitled to receive tiered double digit royalties on global
sales of HuMax-CD20"

[gentogen]

I tillægsaftalen fra 2010 hedder det, at "Genmab will forego development milestones for autoimmune indications and the first two sales milestones while retaining a double digit royalty on sales"

[bibob]

Lidt fra " Tante Berlinger " https://www.berlingske.dk/www.berlingske.dk/tre-scenarier-for-aktiemarkederne-efter-det-amerikanske

[Bella1]

"med livrem og seler:-)

[E_L]

I can't remember if this Teprotumumab update was posted http://ir.horizon-pharma.com/news-releases/news-release-details/horizon-pharma-plc-announces-presentation-results-48-week?_ga=2.118113481.1921129680.1541499979-967984457.1541499979

[E_L]

"The analysis of this Phase 2 exploratory endpoint shows that 69.2percent (18/26 patients) of those with diplopia improvements of at leastone grade at week 24 maintained these improvements at week 72 (48 weeksfollowing treatment period)."

[Helge_LarsenPI-redaktør]

"I think it is worth highlighting Genmab as a company that has made it all the way – and in my view has been very successful in bringing a product to the market and has developed into a company with a lot of attention – also generalist investors. Due to its size it has meant a lot in shaping a market for biotechs in the Nordics and proven that it can be done" . http://app.n.nasdaq.com/e/es?s=1981692173&e=82533&elqTrackId=779951e9dfa7432ab00e909c98de7ed0&elq=294d18ca9aee40aeae7b9bd1bf0d9ee8&elqai

[henrik48]

Berettiget ros til Genmab

[peter12]

SITC har frigivet abstracts i dag og dara bliver nævnt ifm CLL https://www.sitcancer.org/2018/abstracts/titles